<DOC>
	<DOCNO>NCT01845636</DOCNO>
	<brief_summary>Odor identification deficit , result early Alzheimer 's Disease ( AD ) pathology olfactory bulb tract well olfactory projection area medial temporal lobe ( entorhinal piriform cortex hippocampus ) , lateral central orbitofrontal cortex several region , occur AD strongly predict mild cognitive impairment ( MCI ) conversion AD . Our pilot data , along converge finding literature , suggest odor identification deficit , incremental change time change response anticholinergic challenge , may clinically simple , relatively inexpensive , predictor cognitive improvement acetylcholinesterase inhibitor ( ACheI ) treatment potential clinical implication predict improvement monitoring ACheI therapy .</brief_summary>
	<brief_title>Olfactory Deficits MCI Predictor Improved Cognition Donepezil</brief_title>
	<detailed_description>In clinical trial , investigator evaluate , treat follow broad sample 60 adult patient amnestic MCI New York State Psychiatric Institute/Columbia University Medical Center . Recruitment clinic and/or advertisement . In protocol , 60 amnestic MCI patient receive baseline memory olfactory assessment begin treatment donepezil . Patients follow total 1 year . During time , patient monitor closely study physician receive memory olfactory assessment week 8 , 26 , 52 . In addition , olfactory challenge test do baseline . This project value selection patient mild cognitive impairment treatment base evaluation olfaction test predict response donepezil ACheI . Since mild cognitive impairment widespread Alzheimer 's disease represent major public health problem , study considerable public purpose significance .</detailed_description>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Atropine</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Of either sex , age 5595 year old Patients meet criterion amnestic mild cognitive impairment meeting follow : ( ) subjective memory complaint ( ii ) Wechsler Memory ScaleR Logical Memory combine Story A + B immediate recall score combine Story A + B delay recall score Free Cued Selective Reminding Test immediate recall delay recall score great 1.5 Standard Deviation ( SD ) norm Selective Reminding Test immediate recall delay recall score great 1.5 SD norm iii ) functional impairment consistent dementia Folstein Mini Mental State ( MMSE ) score â‰¥ 23 30 Clinical Dementia Rating ( CDR ) 0.5 ( questionable dementia ) Availability informant Meets Criteria dementia Diagnostic Statistical Manual IV ( DSMIV ) criteria probable Alzheimer 's disease Meets DSM IV criterion : ( ) schizophrenia , schizoaffective disorder , psychosis , bipolar I disorder ( ii ) alcohol substance dependence abuse ( current within past 6 month ) Current untreated major depression suicidality Parkinson 's disease , Lewy body disease , multiple sclerosis , central nervous system infection , Huntington 's disease , amyotrophic lateral sclerosis , major neurological disorder . Mental Retardation Clinical stroke residual neurological deficit . MRI find cerebrovascular disease ( small infarct , lacunes , periventricular disease ) absence clinical stroke residual neurological deficit lead exclusion . Patients receive cholinesterase inhibitor ( donepezil , rivastigmine , galantamine ) memantine exclude . Acute , severe , unstable medical illness . For cancer , patient active illness metastasis exclude , past history successfully treat cancer lead exclusion . Medical contraindication donepezil treatment prior history intolerability donepezil treatment . Medications anticholinergic effect show adversely impact cognition permit . Benzodiazepines lorazepam equivalent great equal 2 mg daily narcotic also permit . Exclusion criterion olfaction : history anosmia due cause ( e.g . traumatic congenital ) verify UPSIT score &lt; 11 40 ; head trauma loss consciousness ; nasal sinus disease , current upper respiratory infection ; severe allergy odor ; current smoker &gt; 1 pack daily .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Olfaction</keyword>
	<keyword>Donepezil</keyword>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Mild Cognitive Impairment</keyword>
	<keyword>Memory</keyword>
</DOC>